Expression of major vault protein gene in osteosarcorna patients

• Autor(a) principal: Dalla Torre, Cristiane Arruda [UNIFESP]
• Data de Publicação: 2007
• Outros Autores: Toledo, Silvia Regina Caminada de [UNIFESP], Yoshimoto, Maisa, Petrilli, Antonio Sergio [UNIFESP], Andrade, Joyce Anderson Duffles [UNIFESP], Chilton-MacNeill, Susan, Squire, Jeremy A., Zielenska, Maria
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1002/jor.20371; http://repositorio.unifesp.br/handle/11600/29826
• topic: osteosarcoma; MVP gene; drug resistance; gene expression

Osteosarcoma (CS) is a primary malignant tumor of bone. Despite the successful use of multiple chemotherapeutic agents in the treatment of OS, more than 30% of OS tumors remain resistant to treatment. Elucidation of cellular resistance mechanisms may lead to better treatments for cancer patients. in this study, we used the low-density expression cDNA array, GEArray Q Series Human Cancer Drug Resistance and Metabolism Gene Array to screen genes related to drug resistance in 15 OS tumors. Expression patterns of the MPV gene were validated by real time PCR on 45 OS patient tumor samples and correlated with clinical and pathological data. Major vault protein (MVP) expression was present in 24 (53%) tumor samples and absent in 21 (47%). Samples from surgery showed correlation between the expression of MVP, metastatic disease at diagnosis and event free survival (EFS). the MVP gene expression correlates with metastatic disease at diagnosis after neoadjuvant chemotherapy (p = 0.048), and is also associated with worse EFS (p = 0.036). These findings suggest that MVP expression is involved in one of the mechanisms of drug resistance in OS and is induced by chemotherapy. (c) 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.